Tourette Syndrome (TS) Emerging Therapy and TPP Insights

Thelansis’s “Tourette Syndrome (TS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Tourette Syndrome (TS) Overview

Tourette syndrome (TS) is a complex neurodevelopmental disorder clinically defined by the presence of multiple motor tics and at least one vocal (phonic) tic that persist and fluctuate in severity for more than a year, with an onset prior to age 18. The underlying pathophysiology is strongly linked to dopamine dysregulation within the cortico-striato-thalamo-cortical (CSTC) circuitry. TS falls under the broader spectrum of tic disorders, which modern diagnostic frameworks classify alongside Provisional Tic Disorder (lasting less than a year) and Persistent Motor or Vocal Tic Disorder. Clinically, TS follows a classic waxing and waning course, typically peaking during early adolescence, and is highly associated with neurobehavioral comorbidities, most notably ADHD and OCD. Because there are currently no disease-modifying therapies to cure the root neurological dysfunction, management is strictly symptom-directed; the modern standard of care prioritizes Comprehensive Behavioral Intervention for Tics (CBIT), strategically escalating to targeted pharmacotherapy—such as alpha-2 adrenergic agonists, dopamine antagonists, or VMAT2 inhibitors—only when tics cause profound physical discomfort or significantly disrupt psychosocial functioning.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)